Ustekinumab Archives - Medical Conferences

Risankizumab influences key pathogenic Th17 cells in CD

Presented By

Dr Daniele Noviello, University of Milan, Italy

Trial

SEQUENCE

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

Extending ustekinumab dosing interval does not influence drug survival in IBD

Presented By

Dr Monique Devillers, Erasmus University Medical Center, the Netherlands

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:22

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

How close are we to personalised medicine in psoriatic arthritis?

Presented By

Prof. Ennio Lubrano, University of Molise, Ital

Conference

IFPA 2024

Type

News article

17 July 2024 14:38

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

SEQUENCE: Risankizumab versus ustekinumab across endpoints

Presented By

Prof. Marla Dubinsky, Mount Sinai Hospital, NY, USA

Trial

Phase 3, SEQUENCE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:45

Biologicals and JAK inhibitors hold promise in microscopic colitis

Presented By

Dr Bram Verstockt, University Hospitals Leuven, Belgium

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:35

Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease

Presented By

Dr Jordi Guardiola, University Hospital Bellvitge, Spain

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:33

How effective is dose escalation of biologicals in IBD?

Presented By

Dr Cristina Rubín de Célix, University Hospital La Princesa, Spain

Trial

RAINBOW-IBD

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:30

Interview: Medicare’s first drug price negotiations: concerning?

Expert

Prof. Marc Bonaca, University of Colorado, USA

4 January 2024 15:06

SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD

Presented By

Prof. Laurent Peyrin-Biroulet, University Hospital of Nancy, France

Trial

Phase 3, SEQUENCE

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:44

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease

Presented By

Prof. Marc Ferrante, KU Leuven, Belgium

Trial

EVOLVE

Conference

DDW 2023

Type

News article

13 June 2023 13:56

Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure

Presented By

Prof. Mathurin Fumery, Amiens University Hospital, France

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:55

Long-term data supports the established efficacy and safety of ustekinumab in UC

Presented By

Prof. Silvio Danese , Vita-Salute San Raffaele University, Italy

Trial

UNIFI LTE UNIFI LTE

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:21

New insights into psoriasis comorbidity

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:12

Comparable safety profiles of biological therapies in elderly patients with IBD

Presented By

Dr Gustavo Drügg Hahn, McGill University Health Center, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:22

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By

Dr Neeraj Narula, McMaster University, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:46

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By

Prof. Remo Panaccione , University of Calgary, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:44

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, GALAXI-1

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:21

Potential biomarker discovered for treatment response to ustekinumab

Presented By

Mr Shane Solanky, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 15:46

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By

Dr Charlie Bridgewood, University of Leeds, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:51

Risankizumab superior to ustekinumab in skin histopathology scores

Presented By

Dr Kathleen Smith

Trial

Phase 3, UltiMMa-1 trial

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:49

Tapering biologics: No alarming signs of increased anti-drug antibodies

Presented By

Dr Juul van den Reek , Radboudumc, the Netherlands

Trial

Phase 4, CONDOR

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:43

HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

Presented By

Dr Oras Alabas, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:05

Ustekinumab: highly efficacious in PSA independent of methotrexate

Presented By

Dr Michaela Köhm, Goethe-University Frankfurt, Germany

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:48

Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD

Presented By

Prof. Laurent Peyrin-Biroulet, University Hospital of Nancy, France

Trial

Phase 3, STARDUST

Conference

UEGW 2021

Type

News article

27 October 2021 10:09

ECCO 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECCO 2021

10 August 2021 08:17

Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD

Presented By

Dr Peter Irving, Guy’s and St. Thomas’ Hospital, UK

Trial

SEAVUE

Conference

ECCO 2021

Type

News article

2 July 2021 23:45

Ustekinumab safe and effective in elderly CD patients

Presented By

Dr Diego Casas Deza, Hospital Universitario Miguel Servet

Trial

ENEIDA registry

Conference

ECCO 2021

Type

News article

2 July 2021 22:50

Risk of hospitalisation and surgery linked to IBD biological

Presented By

Dr Camilla Bjørn Jensen, Frederiksberg Hospital

Conference

ECCO 2021

Type

News article

2 July 2021 20:20

Allergies: an underrated factor in alopecia pathogenesis

Presented By

Prof. Natasha Mesinkovska, UC Irvine School of Medicine, CA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:45

Bimekizumab in psoriasis: Up-and-coming

Presented By

Prof. Bruce Strober, Yale University, USA

Trial

Phase 3, BE VIVID

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:34

First randomised T2T trial using endoscopy to guide dose escalation

Principal Investigator

Prof. Silvio Danese, Humanitas University, Italy

Trial

Phase 3, STARDUST

Conference

UEGW 2020

Type

News article

2 November 2020 11:00

Biologics in HS – a growing armamentarium

Presented By

Prof. Joslyn Kirby, Penn State University, USA

Trial

PIONEER

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 12:48

Psoriasis therapy for children and pregnancies

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

CRIB, CADMUS, IXORA-PEDS

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 08:03

IL-17A and IL-17F blockade remarkably effective in psoriasis

Presented By

Prof. Kristian Reich; Prof. Kenneth B. Gordon

Trial

BE VIVID and BE READY

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:09

Vedolizumab, adalimumab, and golimumab compared

Presented By

Dr F.S. Macaluso & Dr A. Casanotti

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:32

Vedolizumab versus ustekinumab

Presented By

Dr H. Alric & Dr V. Biemans

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:28

Ustekinumab in CD: a T2T trial

Presented By

Prof. L. Peyrin-Biroulet, CHRU de Nancy, France

Trial

Phase 3, STARDUST

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:26

Subcutaneous ustekinumab as maintenance therapy in UC

Presented By

Dr R. Panaccione & Dr W.J. Sandborn

Trial

UNIFI

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:22

Impact of biologicals on faecal microbiota

Presented By

C. Caenepeel, KU Leuven, Belgium

Conference

ECCO 2020

14 April 2020 10:20

Lowest risk of infection after therapy with an IL-12/IL-23 blocker

Presented By

Dr Yinzhu Jin, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA

Trial

Cohort study

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:42

Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib

Presented By

Dr Evelyne Vinet, McGill University, Montreal, Canada

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:12

Biologics: increasingly used in paediatric dermatology

Presented By

Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 15:16

Ustekinumab is safe and effective in ulcerative colitis: 2-year data

Presented By

Prof. Bruce Sands, Icahn School of Medicine at Mount Sinai, New York, USA

Trial

Phase 3, UNIFI

Conference

UEGW 2019

Type

Peer-reviewed article

23 October 2019 22:10

Subcutaneous ustekinumab as maintenance therapy in UC

Presented By

Prof. Silvio Danese, Humanitas University, Milan, Italy

Conference

UEGW 2019

Type

Peer-reviewed article

23 October 2019 18:43

New targets and biologics for cutaneous lupus erythematosus

Presented By

Prof. Victoria P. Werth, University of Pennsylvania, USA

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 15:59

Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies

Presented By

Dr Sandra Philipp, Charité-Universitätsmedizin Berlin, Germany

Trial

Phase 3, AMAGINE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 21:59

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients

Presented By

Dr Sandra Phillip, Charité-Universitätsmedizin Berlin, Germany

Trial

Phase 3, CADMUS Jr

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 19:59

Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies

Presented By

Prof. Lluís Puig, Hospital de la Santa Creu i Sant Pau, Spain

Trial

Phase 3, AMAGINE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 15:29

Ustekinumab as maintenance therapy and with shortened interval

Trial

Phase 3, UNIFI

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 20:11

Molecular effects of ustekinumab

Trial

Phase 3, UNITI

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 19:47

Psoriasis and Biologics: The Beat Goes On

Presented By

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:06

ILC1 distribution predicts response to ustekinumab

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 22:58

Comparative effectiveness of vedolizumab and ustekinumab in CD

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 16:01